[{"id":"cb2c4839-09e4-41a3-9033-1bd13594665c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01860937","created_at":"2021-01-18T08:19:12.565Z","updated_at":"2024-07-02T16:34:38.169Z","phase":"Phase 1","brief_title":"T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01860937","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • IKZF1 deletion","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • IKZF1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"937bec61-abb0-4838-bc7e-ee7138f0f459","acronym":"MED20-165","url":"https://clinicaltrials.gov/study/NCT04512716","created_at":"2021-01-18T21:37:46.095Z","updated_at":"2024-07-02T16:35:15.633Z","phase":"Phase 1","brief_title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04512716 - MED20-165","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-08"},{"id":"7124de59-2bb5-47fc-88d8-620c43bf958f","acronym":"ORBIT","url":"https://clinicaltrials.gov/study/NCT02973191","created_at":"2021-01-18T14:36:55.494Z","updated_at":"2024-07-02T16:37:23.628Z","phase":"Phase 1/2","brief_title":"A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02973191 - ORBIT","lead_sponsor":"Celgene","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/20/2016","start_date":" 12/20/2016","primary_txt":" Primary completion: 06/25/2019","primary_completion_date":" 06/25/2019","study_txt":" Completion: 01/24/2021","study_completion_date":" 01/24/2021","last_update_posted":"2017-04-10"}]